Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

Alopexx, Inc.

CIK 1880995Updated Nov 9, 2026

No exchange listing on record for this SEC filer. Coverage is drawn from its filings.

Filing activity

SEC EDGAR
Latest filing

S-1/A · Nov 6, 2026

27 filings on record · S-1/A, FWP, 8-A12B, S-1, DRS.

About the company

We are a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). That target has been found on an expanding number of pathogens. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management’s assessment that the broad-spectrum potential of our therapeutics will allow them to be used for the prevention, treatment, and mitigation of a wide range of infections. In a first-in-man trial, our vaccine candidate, AV0328, was found to be well tolerated with no serious adverse events observed. It was noted to induce antibodies in human serum that were effective, in laboratory studies, in killing all PNAG-expressing pathogens tested. We believe our vaccine’s broad-spectrum potential will allow it to be used for the long-term prevention of a wide range of infections including pneumococcal pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), meningitis, and sexually transmitted diseases. Similarly, our fully human mo…

S-1/A · 2026-11-06 · 0001213900-26-116942

Company description from the cited filing.

Recent filings

  1. S-1/A filing

    S-1/A · 2026-11-06 · 0001213900-26-116942

  2. S-1/A filing

    S-1/A · 2026-10-27 · 0001213900-26-112569

  3. S-1/A filing

    S-1/A · 2026-09-17 · 0001213900-26-101026

  4. S-1/A filing

    S-1/A · 2026-08-17 · 0001213900-26-090319

  5. S-1/A filing

    S-1/A · 2026-06-26 · 0001213900-26-072480

Show 5 more recent filings
  1. S-1/A filing

    S-1/A · 2025-02-25 · 0001213900-25-016709

  2. S-1/A filing

    S-1/A · 2025-01-08 · 0001839882-25-001330

  3. S-1/A filing

    S-1/A · 2024-09-09 · 0001999371-24-011702

  4. S-1/A filing

    S-1/A · 2024-03-14 · 0001999371-24-003528

  5. S-1/A filing

    S-1/A · 2023-12-27 · 0001999371-23-001220

Offerings

Registration 333-263328

S-1/A · 2026-11-06 · 0001213900-26-116942

Terms from the governing filing for this registration; not a claim that the offering is open today.

Underwriters: ThinkEquity LLC

Filing attachments

ex107.htm · S-1/A · 2025-01-08

EX-FILING FEES 9 ex107.htm CALCULATION OF FILING FEE TABLE ALOPEXX, INC. S-1/A Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Alopexx, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Security Fee Amount Proposed Maximum …

S-1/A · 2025-01-08 · 0001839882-25-001330

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.